<DOC>
	<DOC>NCT00839852</DOC>
	<brief_summary>This is an outpatient study to evaluate the long-term safety, tolerability, and pharmacokinetics of cariprazine in patients with Schizophrenia.</brief_summary>
	<brief_title>The Purpose of the Study is to Determine Whether Cariprazine is a Safe and Tolerated Long-term Treatment in Patients With Chronic Stable Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>Patients who have completed the doubleblind treatment period of the leadin study (RGHMD16) Patients who have responded to doubleblind treatment in the leadin study as outpatients (at least 20% reduction relative to Visit 2 in the leadin study in PANSS total score and a CGIS of less than or equal to 3 Patients eligible to continue as outpatients based on the opinion of the Principal Investigator Patients must have a caregiver to ensure treatment compliance Patients with clinically significant abnormalities on physical examination, laboratory, vital signs,and/ or ECG</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>61 Years</maximum_age>
	<verification_date>September 2011</verification_date>
</DOC>